1. Home
  2. VNDA vs DCTH Comparison

VNDA vs DCTH Comparison

Compare VNDA & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$6.00

Market Cap

411.3M

Sector

Health Care

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$10.86

Market Cap

363.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VNDA
DCTH
Founded
2002
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
411.3M
363.5M
IPO Year
2005
2015

Fundamental Metrics

Financial Performance
Metric
VNDA
DCTH
Price
$6.00
$10.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$14.90
$22.00
AVG Volume (30 Days)
1.1M
388.6K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.53
EPS
N/A
N/A
Revenue
$216,105,000.00
N/A
Revenue This Year
$21.35
$24.54
Revenue Next Year
$37.40
$33.15
P/E Ratio
N/A
N/A
Revenue Growth
8.72
N/A
52 Week Low
$4.14
$8.12
52 Week High
$9.91
$18.19

Technical Indicators

Market Signals
Indicator
VNDA
DCTH
Relative Strength Index (RSI) 33.15 49.81
Support Level $5.73 $10.22
Resistance Level $7.76 $11.14
Average True Range (ATR) 0.30 0.55
MACD -0.07 -0.07
Stochastic Oscillator 2.83 33.72

Price Performance

Historical Comparison
VNDA
DCTH

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: